Form 8-K · Current report
Charles River Laboratories 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0001100682
- Accession no.
- 0001100682-26-000156
Summary
Charles River Laboratories reported third-quarter 2026 revenue of $982.7 million, down 2.2% from a year earlier but up 4.7% organically, with GAAP earnings per share of $6.86 and non-GAAP earnings per share of $3.09. The company raised its 2026 revenue and earnings guidance, citing better-than-expected performance in its Discovery and Safety Assessment segment and a lower tax rate.
Key points
- Third-quarter non-GAAP operating margin rose 330 basis points to 23.0%, and GAAP operating margin rose 730 basis points to 20.6%.
- GAAP net income of $333.1 million included a $245.6 million benefit, or $5.06 per share, from reversal of acquired tax reserves after newly enacted tax legislation and completion of tax requirements in a foreign jurisdiction.
- 2026 guidance was raised to organic revenue growth of at least 1.5% and non-GAAP earnings per share of $11.35 to $11.55.
- CEO Birgit Girshick said biopharmaceutical demand remained strong, with year-over-year increases in DSA net bookings and proposals.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02. Results of Operations and Financial Condition On November 4, 2026, Charles River Laboratories International, Inc. issued a press release providing financial results for the third quarter ended September 26, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein. The information contained in the accompanying Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.